HRP20170328T1 - Cjepivo pcsk9 - Google Patents
Cjepivo pcsk9 Download PDFInfo
- Publication number
- HRP20170328T1 HRP20170328T1 HRP20170328TT HRP20170328T HRP20170328T1 HR P20170328 T1 HRP20170328 T1 HR P20170328T1 HR P20170328T T HRP20170328T T HR P20170328TT HR P20170328 T HRP20170328 T HR P20170328T HR P20170328 T1 HRP20170328 T1 HR P20170328T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- pcsk9
- fragments
- vaccine according
- sipwnleritpr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (10)
1. Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 153 do 165 od PCSK9 u skladu sa SEQ ID NO:9, i gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 209 do 222 od PCSK9 u skladu sa SEQ ID NO:9.
2. Cjepivo prema zahtjevu 1, naznačeno time, da su najmanje dva fragmenta odabrana iz skupine sastavljene od peptida koji imaju aminokiselinsku sekvencu SIPWNLERITPPR (SEQ ID NO:2), PEEDGTRFHRQASK (SEQ ID NO:3), PEEDGTRFHRQA (SEQ ID NO:4), EEDGTRFHRQASK (SEQ ID NO:5), EEDGTRFHRQAS (SEQ ID NO:6), SIPWNLERITP (SEQ ID NO:7) i SIPWNLERIT (SEQ ID NO:8).
3. Cjepivo prema zahtjevu 1 ili 2, naznačeno time, da najmanje jedan fragment od PCSK9 ima aminokiselinsku sekvencu odabranu iz skupine koju čine SIPWNLERITPPR (SEQ ID NO:2), SIPWNLERITP (SEQ ID NO:7) i SIPWNLERIT (SEQ ID NO:8), i najmanje jedan fragment od PCSK9 ima aminokiselinsku sekvencu odabranu iz skupine koju čine PEEDGTRFHRQASK (SEQ ID NO:3), PEEDGTRFHRQA (SEQ ID NO:4), EEDGTRFHRQASK (SEQ ID NO:5) i EEDGTRFHRQAS (SEQ ID NO:6).
4. Cjepivo prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da cjepivo obuhvaća SIPWNLERITPPR (SEQ ID NO:2) i PEEDGTRFHRQASK (SEQ ID NO:3), SIPWNLERITPPR (SEQ ID NO:2) i PEEDGTRFHRQA (SEQ ID NO:4), SIPWNLERITPPR (SEQ ID NO:2) i EEDGTRFHRQASK (SEQ ID NO:5), SIPWNLERITPPR (SEQ ID NO:2) i EEDGTRFHRQAS (SEQ ID NO:6), PEEDGTRFHRQASK (SEQ ID NO:3) i SIPWNLERITP (SEQ ID NO:7), PEEDGTRFHRQASK (SEQ ID NO:3) i SIPWNLERIT (SEQ ID NO:8), PEEDGTRFHRQA (SEQ ID NO:4) i SIPWNLERITP (SEQ ID NO:7), PEEDGTRFHRQA (SEQ ID NO:4) i SIPWNLERIT (SEQ ID NO:8), EEDGTRFHRQASK (SEQ ID NO:5) i SIPWNLERITP (SEQ ID NO:7), EEDGTRFHRQASK (SEQ ID NO:5) i SIPWNLERIT (SEQ ID NO:8), EEDGTRFHRQAS (SEQ ID NO:6) i SIPWNLERITP (SEQ ID NO:7), ili EEDGTRFHRQAS (SEQ ID NO:6) i SIPWNLERIT (SEQ ID NO:8).
5. Cjepivo prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da najmanje dva fragmenta od PCSK9 sadrže cisteinski ostatak na C-završnom kraju i/ili na N-završnom kraju.
6. Cjepivo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da su najmanje dva fragmenta od PCSK9 spojena na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).
7. Cjepivo prema bilo kojem od zahtjeva 1 do 6, naznačeno time, da su najmanje dva fragmenta od PCSK9 formulirana za intradermalnu, subkutanu ili intramuskularnu primjenu.
8. Cjepivo prema bilo kojem od zahtjeva 1 do 7, naznačeno time, da cjepivo obuhvaća najmanje jedno pomoćno sredstvo, poželjno aluminijev hidroksid.
9. Cjepivo prema bilo kojem od zahtjeva 1 do 8, naznačeno time, da se upotrebljava u liječenju i/ili u prevenciji kardiovaskularnih bolesti, moždanog udara, okluzivnih bolesti perifernih arterija, koronarne srčane bolesti, apoplektičkog cerebralnog napada ili perifernih vaskularnih bolesti.
10. Cjepivo prema zahtjevu 9, naznačeno time, da se najmanje dva fragmenta od PCSK9 daju pojedincu po jednoj dozi, u količini od 0,1 ng do 10 mg, poželjno od 1 μg do 500 μg.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11181090.9A EP2570135B1 (en) | 2011-09-13 | 2011-09-13 | PCSK9 Vaccine |
| PCT/EP2012/067950 WO2013037889A2 (en) | 2011-09-13 | 2012-09-13 | Vaccine |
| EP12759427.3A EP2755678B1 (en) | 2011-09-13 | 2012-09-13 | Pcsk9 vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170328T1 true HRP20170328T1 (hr) | 2017-05-19 |
Family
ID=46851983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170328TT HRP20170328T1 (hr) | 2011-09-13 | 2012-09-13 | Cjepivo pcsk9 |
| HRP20160392TT HRP20160392T1 (hr) | 2011-09-13 | 2016-04-15 | Cjepivo pcsk9 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160392TT HRP20160392T1 (hr) | 2011-09-13 | 2016-04-15 | Cjepivo pcsk9 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9220762B2 (hr) |
| EP (2) | EP2570135B1 (hr) |
| JP (1) | JP6054400B2 (hr) |
| KR (1) | KR101983685B1 (hr) |
| CN (1) | CN103874504B (hr) |
| AU (1) | AU2012307348B8 (hr) |
| BR (1) | BR112014005756A2 (hr) |
| CA (1) | CA2848487A1 (hr) |
| CY (2) | CY1117335T1 (hr) |
| DK (2) | DK2570135T3 (hr) |
| ES (2) | ES2565757T3 (hr) |
| HR (2) | HRP20170328T1 (hr) |
| HU (2) | HUE028583T2 (hr) |
| IL (1) | IL231043A (hr) |
| LT (1) | LT2755678T (hr) |
| MX (1) | MX346883B (hr) |
| PL (2) | PL2570135T3 (hr) |
| PT (1) | PT2755678T (hr) |
| RS (1) | RS54639B1 (hr) |
| RU (2) | RU2017139094A (hr) |
| SG (1) | SG11201400086QA (hr) |
| SI (2) | SI2570135T1 (hr) |
| SM (1) | SMT201600082B (hr) |
| WO (1) | WO2013037889A2 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2703483A1 (en) * | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
| WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
| JP6494667B2 (ja) * | 2014-02-28 | 2019-04-03 | アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ | Ｐｃｓｋ９ワクチン |
| CN105085684B (zh) * | 2014-05-14 | 2020-04-17 | 上海亨臻实业有限公司 | Pcsk9靶向重组疫苗设计及其应用 |
| CN106822881A (zh) * | 2016-12-09 | 2017-06-13 | 四川大学 | 一种针对pcsk9的抗高血脂蛋白疫苗 |
| BR112019020148A2 (pt) | 2017-04-13 | 2020-05-05 | Cadila Healthcare Limited | peptídeo |
| CN107488215A (zh) * | 2017-07-19 | 2017-12-19 | 邱志华 | 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗 |
| AU2021214166A1 (en) * | 2020-01-28 | 2022-09-22 | United Biomedical, Inc. | Peptide immunogens targeting PCSK9 and formulations thereof for prevention and treatment of PCSK9-mediated disorders |
| KR20210158693A (ko) * | 2020-06-24 | 2021-12-31 | 바이오스트림테크놀러지스(주) | 항 ｐｃｓｋ９ 항체 및 이의 용도 |
| JPWO2022244845A1 (hr) * | 2021-05-19 | 2022-11-24 | ||
| WO2023161528A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2874149T3 (es) * | 2006-05-11 | 2021-11-04 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para inhibir la expresión del gen PCSK9 |
| CN101679527A (zh) * | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AT507604A1 (de) * | 2008-11-19 | 2010-06-15 | Affiris Forschungs & Entwicklungs Gmbh | Behandlung von atherosklerose |
| PE20161551A1 (es) | 2009-09-03 | 2017-01-18 | Pfizer Vaccines Llc | Vacuna de pcsk9 |
-
2011
- 2011-09-13 RS RS20160183A patent/RS54639B1/sr unknown
- 2011-09-13 HU HUE11181090A patent/HUE028583T2/en unknown
- 2011-09-13 SI SI201130773A patent/SI2570135T1/sl unknown
- 2011-09-13 ES ES11181090.9T patent/ES2565757T3/es active Active
- 2011-09-13 DK DK11181090.9T patent/DK2570135T3/en active
- 2011-09-13 EP EP11181090.9A patent/EP2570135B1/en active Active
- 2011-09-13 PL PL11181090T patent/PL2570135T3/pl unknown
-
2012
- 2012-09-13 AU AU2012307348A patent/AU2012307348B8/en not_active Ceased
- 2012-09-13 PL PL12759427T patent/PL2755678T3/pl unknown
- 2012-09-13 DK DK12759427.3T patent/DK2755678T3/en active
- 2012-09-13 RU RU2017139094A patent/RU2017139094A/ru not_active Application Discontinuation
- 2012-09-13 HR HRP20170328TT patent/HRP20170328T1/hr unknown
- 2012-09-13 HU HUE12759427A patent/HUE031860T2/en unknown
- 2012-09-13 JP JP2014530217A patent/JP6054400B2/ja not_active Expired - Fee Related
- 2012-09-13 WO PCT/EP2012/067950 patent/WO2013037889A2/en not_active Ceased
- 2012-09-13 BR BR112014005756A patent/BR112014005756A2/pt not_active Application Discontinuation
- 2012-09-13 PT PT127594273T patent/PT2755678T/pt unknown
- 2012-09-13 MX MX2014002879A patent/MX346883B/es active IP Right Grant
- 2012-09-13 CN CN201280044571.4A patent/CN103874504B/zh not_active Expired - Fee Related
- 2012-09-13 LT LTEP12759427.3T patent/LT2755678T/lt unknown
- 2012-09-13 SG SG11201400086QA patent/SG11201400086QA/en unknown
- 2012-09-13 EP EP12759427.3A patent/EP2755678B1/en not_active Not-in-force
- 2012-09-13 US US14/344,879 patent/US9220762B2/en not_active Expired - Fee Related
- 2012-09-13 RU RU2014114506A patent/RU2640258C2/ru not_active IP Right Cessation
- 2012-09-13 ES ES12759427.3T patent/ES2618796T3/es active Active
- 2012-09-13 SI SI201230903A patent/SI2755678T1/sl unknown
- 2012-09-13 KR KR1020147009735A patent/KR101983685B1/ko not_active Expired - Fee Related
- 2012-09-13 CA CA2848487A patent/CA2848487A1/en not_active Abandoned
-
2014
- 2014-02-19 IL IL231043A patent/IL231043A/en active IP Right Grant
-
2015
- 2015-10-23 US US14/921,485 patent/US9669079B2/en not_active Expired - Fee Related
-
2016
- 2016-03-22 SM SM201600082T patent/SMT201600082B/xx unknown
- 2016-03-31 CY CY20161100266T patent/CY1117335T1/el unknown
- 2016-04-15 HR HRP20160392TT patent/HRP20160392T1/hr unknown
-
2017
- 2017-03-16 CY CY20171100333T patent/CY1118856T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170328T1 (hr) | Cjepivo pcsk9 | |
| RU2012140704A (ru) | Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция | |
| AR079706A1 (es) | Composiciones, metodos para el tratamiento de enfermedades oculares relacionadas con la angiogenesis y uso | |
| MX2019012884A (es) | Terapia de combinacion. | |
| SA114350179B1 (ar) | لقاح إنزيم بروبروتين كونفرتيز سبتليسن-كيكسين نوع 9 | |
| HRP20171909T1 (hr) | Postupci i sastavi za otkrivanje razine djelovanja lizosomalne eksocitoze i načini njihove uporabe | |
| PE20141727A1 (es) | Composiciones, usos y metodos para tratamiento de trastornos y enfermedades metabolicas | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| JP2013520405A5 (hr) | ||
| RU2012122162A (ru) | Гликолизированная форма аналога антигенного glp-1 | |
| HRP20131229T1 (hr) | Lijeäśenje ateroskleroze | |
| EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| NZ599839A (en) | Synergistic antiviral composition and use thereof | |
| WO2013096868A3 (en) | Saposin-a derived peptides and uses thereof | |
| JP2012102105A5 (hr) | ||
| MX2024009403A (es) | Tetrahidropiridopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead | |
| MX2017006372A (es) | Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matrix extracelular. | |
| PH12012500827A1 (en) | Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| JP2017508006A5 (hr) | ||
| RU2012108179A (ru) | Новый пептид и его применение | |
| NO20084053L (no) | Inhibering av tumorvekst | |
| HRP20181782T2 (hr) | Peptidno cjepivo pcsk9 | |
| MX350145B (es) | Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo. |